These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28282600)

  • 21. Development of a Specific and Sensitive HPAEC-PAD Method for Quantification of Vi Polysaccharide Applicable to other Polysaccharides Containing Amino Uronic Acids.
    Giannelli C; Raso MM; Palmieri E; De Felice A; Pippi F; Micoli F
    Anal Chem; 2020 May; 92(9):6304-6311. PubMed ID: 32330386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
    Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Vi conjugate - a new generation of typhoid vaccine.
    Szu SC
    Expert Rev Vaccines; 2013 Nov; 12(11):1273-86. PubMed ID: 24156285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
    Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
    Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid.
    Ali A; An SJ; Cui C; Haque A; Carbis R
    Hum Vaccin Immunother; 2012 Feb; 8(2):189-93. PubMed ID: 22426380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population impact of Vi capsular polysaccharide vaccine.
    Khan MI; Ochiai RL; Clemens JD
    Expert Rev Vaccines; 2010 May; 9(5):485-96. PubMed ID: 20450323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine.
    An SJ; Yoon YK; Kothari S; Kim DR; Kim JA; Kothari N; Lee E; Park TH; Carbis R
    Vaccine; 2012 Feb; 30(6):1023-8. PubMed ID: 22192846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
    Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
    Front Immunol; 2020; 11():574057. PubMed ID: 33424833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
    Wetter M; Kowarik M; Steffen M; Carranza P; Corradin G; Wacker M
    Glycoconj J; 2013 Jul; 30(5):511-22. PubMed ID: 23053636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
    Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.
    Szu SC; Stone AL; Robbins JD; Schneerson R; Robbins JB
    J Exp Med; 1987 Nov; 166(5):1510-24. PubMed ID: 3681191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH; Kantele JM; Herzog C; Kantele A
    Vaccine; 2014 Jan; 32(5):544-51. PubMed ID: 24342246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. S.Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice.
    Haque S; Sengupta S; Gupta D; Bhan MK; Kumar R; Khan A; Jailkhani B
    Biologicals; 2019 Nov; 62():50-56. PubMed ID: 31606267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune response of S. Typhi-derived Vi polysaccharide and outer membrane protein a conjugate in mice.
    Haque S; Sengupta S; Khan A; Mukhopadhyay AK; Bhan MK; Kumar R; Jailkhani B
    Pediatr Neonatol; 2023 Sep; 64(5):518-527. PubMed ID: 36868948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. O-acetylation of typhoid capsular polysaccharide confers polysaccharide rigidity and immunodominance by masking additional epitopes.
    Hitri K; Kuttel MM; De Benedetto G; Lockyer K; Gao F; Hansal P; Rudd TR; Beamish E; Rijpkema S; Ravenscroft N; Bolgiano B
    Vaccine; 2019 Jun; 37(29):3866-3875. PubMed ID: 31160100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
    Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
    Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.
    Micoli F; Rondini S; Pisoni I; Proietti D; Berti F; Costantino P; Rappuoli R; Szu S; Saul A; Martin LB
    Vaccine; 2011 Jan; 29(4):712-20. PubMed ID: 21115057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use and validation of an NMR test for the identity and O-acetyl content of the Salmonella typhi Vi capsular polysaccharide vaccine.
    Lemercinier X; Martinez-Cabrera I; Jones C
    Biologicals; 2000 Mar; 28(1):17-24. PubMed ID: 10799051
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.